AlQadri Nada G, AlNooh Bayan, AlTewerki Malak M, Almotairi Ahmad, Alajlan Saad
Department of Dermatology, Alfaisal University College of Medicine, Riyadh, SAU.
Department of Dermatology, King Khalid University Hospital, Riyadh, SAU.
Cureus. 2020 Jan 27;12(1):e6790. doi: 10.7759/cureus.6790.
Lupus erythematosus panniculitis (LEP) is a rare variant of cutaneous lupus erythematosus (CLE). It is characterized by the presence of a chronic inflammatory process involving the deep dermis and subcutaneous tissues. It commonly presents as deep indurated nodules or sharply demarcated plaques. Antimalarial medications are considered first-line therapy for most cases of LEP while systemic corticosteroids are saved for more resistant lesions. Intravenous immunoglobulin (IVIG) is made up of concentrated polyclonal immunoglobulin G (IgG) fractionated from the blood of healthy blood donors. Nowadays, it is used for the treatment of numerous autoimmune and systemic inflammatory diseases. In this case, we report the case of a female with multiple LEP and discoid lupus erythematosus (DLE) lesions refractory to multiple standard therapy modalities that responded dramatically to IVIG.
红斑狼疮性脂膜炎（LEP）是皮肤型红斑狼疮（CLE）的一种罕见变体。其特征是存在涉及真皮深层和皮下组织的慢性炎症过程。它通常表现为深部硬结性结节或边界清晰的斑块。抗疟药物被认为是大多数LEP病例的一线治疗药物，而全身用皮质类固醇则用于治疗更具抗性的皮损。静脉注射免疫球蛋白（IVIG）由从健康献血者血液中分离出的浓缩多克隆免疫球蛋白G（IgG）组成。如今，它被用于治疗多种自身免疫性和全身性炎症性疾病。在此病例中，我们报告了一名患有多处LEP和盘状红斑狼疮（DLE）皮损的女性患者，该患者对多种标准治疗方法均无反应，但对IVIG治疗反应显著。
